Market Insights
Allergic conjunctivitis develops when any individual’s eyes come in touch with allergens. In this situation, the eye of the patient becomes red, painful, and feels irritating. The overactive immune system causes the body to release histamine and other active compounds through mast cells, resulting in symptoms. Long-term inflammation may cause huge red bumps in the inner lining of your upper eyelids, known as papillae, and your cornea may be injured. Some people may require allergy testing to identify the allergen before changing their behavior.
Allergic conjunctivitis is an inflammation of the eye’s lining that is caused due to the allergens such as those found in pollen. The disease usually affects 30% of the general population of the world. It usually improves in 2 to 4 days without therapy, although it can take up to 1 to 2 weeks to entirely disappear. In the case of bacterial conjunctivitis, an antibiotic is prescribed for the patient, which is usually given topically as an ointment or eye drops.
Report Key Takeaways
Recommended Treatment/Medications for Allergic Conjunctivitis
Antihistamines are taken in the form of eye drops or oral. Antihistamines effectively block histamines. When the immune system reacts to a foreign substance, histamines are produced. People who take it for the first time are advised to avoid driving or handling any heavy machinery until getting used to the drug.
Mast cell stabilizers usually require time to operate on the human body compared to antihistamines, but their effects stay for a long time. They are widely available in the form of eye drops. Some patients use antihistamines and mast cell stabilizers. The antihistamines provide some relief from symptoms before the stabilizers start acting.
Corticosteroids are rarely prescribed by healthcare experts and taken in extreme cases. Synthetic corticosteroids can help to reduce swelling and boost the immune system. Corticosteroids should be used under the observation of a medical expert and only for a short period.
Recent Developments Related to Allergic Conjunctivitis
Aldeyra Therapeutics has conducted Phase 3 TRANQUILITY-2 intended for the clinical trial of reproxalap to treat the dry eye condition. The clinical package is projected to provide unrivaled breadth in terms of acute trials within two days period and chronic trials that last for 12 weeks, as well as a field-based assessment.
The FDA has accepted a supplemental new drug application to add an indication for treating ocular irritation associated with allergic conjunctivitis. The approval is based on the findings of three vehicle-controlled, randomized, multi-center, double-masked, parallel-group investigations.
Major Players Working on Allergic Conjunctivitis
Some companies working on the research and solution development for allergic conjunctivitis are Allergan, Alcon, Novartis AG., Auven Therapeutics, Bausch & Lomb Incorporated, Eton Pharmaceutical, and Sun Pharmaceutical Industries Ltd., Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, etc.
